Thank you for your interest in the Immunolight Cancer Therapy (ICT) Study
The Immunolight Cancer Therapy (formerly X-PACT 10) study is an experimental treatment to treat advanced solid cancerous tumors.
If you have this type of cancer and your cancer is metastatic, recurrent or not responsive to conventional therapy and you would like to (1) learn more about the study (2) learn where the study is being conducted (3) to see if you may qualify for the study, please complete the form below and one of our clinical study experts will call or email you to answer any questions you may have and help you navigate the clinical trial process.
This study uses an investigational therapy called Immunolight Cancer Therapy (formerly X-PACT) which is a combination product, meaning there is both a drug and a medical device. The device consists of phosphors (a substance which when exposed to low dose X-ray, emits light) and a drug called methoxsalen (psoralen), a naturally occurring botanical, to your cancerous tumor via an injection. The area of your tumor injected will then be exposed to low dose X-ray energy (via an X-ray machine), which causes the phosphors to emit light, which activates the drug inside your tumor. Importantly, this is a non-chemotherapy based treatment.
The drug, methoxsalen, currently has FDA and International approvals for a type of cancer called lymphoma, and has been studied for over 50 years in numerous other diseases. The ICT system leverages on the long history of safe and effective use of the drug for a new use – to treat solid tumors.
By submitting this form I accept the Terms of Use and Privacy Policy.
Additional Resources
X-Ray Psoralen Activated Cancer Therapy (X-PACT)
This article summarizes the early development work of the X-PACT system. The effect on cell death in cancer cell lines, as well as the (in-vivo) effects on tumors in mouse studies are described.
Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
The HER2 receptor is a validated oncology target, currently used with current FDA approved targeted therapies. Psoralen also binds to the HER2 receptor and induces cell death in cancers expressing HER2.
Extracorporeal Photopheresis—An Overview
This article summarizes decades of studies using psoralen, activated outside the body, in numerous diseases and disorders.
Extracorporeal photopheresis: Past, present, and future
This article further describes clinical trials and studies using psoralen in multiple diseases. Safety and effectiveness are described in both cancer and autoimmune disorders.
Psoralen photobiology and photochemotherapy: 50 years of science and medicine
This 1998 article describes the 50 year anniversary of using psoralen, in the oral formulation, to treat refractory psoriasis.
Thank you for your inquiry. We will get back to you within two business days.
– The Immunolight Team